Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 12/20 | 0.34 |
| ▸ | CRY1 | Q16526 | 12/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 12/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL928210 | 0.98 | PER2 (0.33) | ALOX15PER2CRY1CRY2PDK2 | |
| SCHEMBL22319660 | 0.93 | CRY1 (0.36) | ALOX15PER2CRY1CRY2 | |
| SCHEMBL731034 | 0.79 | PER2 (0.35) | PER2CRY1CRY2PDK2 | |
| SCHEMBL14778446 | 0.77 | PER2 (0.34) | PER2CRY1CRY2PDK2 | |
| SCHEMBL17556143 | 0.77 | PER2 (0.34) | PER2CRY1CRY2PDK2 | |
| SCHEMBL5618249 | 0.77 | PER2 (0.34) | PER2CRY1CRY2PDK2 | |
| SCHEMBL12251949 | 0.77 | PER2 (0.34) | PER2CRY1CRY2PDK2OPRM1 | |
| SCHEMBL2814302 | 0.77 | PER2 (0.37) | PER2CRY1CRY2PDK2 | |
| SCHEMBL15473862 | 0.77 | HTR5A (0.32) | PER2CRY1CRY2 | |
| SCHEMBL728955 | 0.76 | PER2 (0.33) | PER2CRY1CRY2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-04-05 | — | — | US | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| EP-1996590-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010011959-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2009123194-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | ALOX15 4501/4885PER2 1938/4885CRY1 1110/4885 |
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | ALOX15 1969/4885PER2 857/4885CRY1 380/4885 |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | ALOX15 2872/4885PER2 1874/4885CRY1 2699/4885 |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | ZC3HAV1, IL5, TYMP | ALOX15 2872/4885PER2 1874/4885CRY1 2699/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | ALOX15 4482/4885PER2 2034/4885CRY1 1152/4885 |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ALOX15 2962/4885PER2 3548/4885CRY1 4280/4885 |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | ALOX15 2872/4885PER2 1874/4885CRY1 2699/4885 |
| US-20110015225-A1 | Heterocyclic compound | MC1R, MCHR1, MCHR2 | ALOX15 992/4885PER2 1098/4885CRY1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.